The messy data landscape in the pharmaceutical industry means that newly developed, life-saving drugs can take over a year to get into the hands of patients that need them. Market Access teams have a laborious task producing documentary for regulatory approval, as well as drug pricing and reimbursement strategies. As a result, pharmaceutical companies often spend hundreds of thousands of dollars to access essential pricing and market data or hire third-party support to complete it.

Cellbyte has developed an AI-native platform for teams involved in drug launches, which allows them to effortlessly analyse millions of data points in real time across clinical, pricing, HTA and regulatory data, as well as internal company sources. By providing fast, reliable and high-quality insights, Cellbyte helps prepare documents, determine effective launch sequences and go-to-market strategies at a dramatically reduced timeline.

Legacy databases were built before the LLM era and only surface the most accessible layer of data, missing the depth that pricing and market access teams need. Cellbyte’s AI platform goes further by providing the most comprehensive, up-to-date, and interconnected data foundation, which streamlines a multitude of high-stakes workflows. Processes that previously took up to a year now take minutes without compromising quality.

Felix Steinbrenner, Co-CEO and Co-Founder at Cellbyte said: “The success of a drug’s entire lifecycle is decided in its launch sequence. Insights derived from gigabytes of accurate, up-to-date information are needed to make the best decisions for a launch. The traction Cellbyte has secured with some of the world’s biggest pharmaceutical companies since its launch shows the industry is ready to rethink drug launch workflows and adopt faster, higher quality and cost-effective processes.” 

Daniel Moreira, Co-CEO and Co-Founder at Cellbyte said: “Based on my years in Life Science Consulting, I’ve seen countless innovations transforming clinical development. Yet in Pricing and Market Access, decisions still too often rely on manual work and anecdotal evidence even though information is so abundant. Now, generative AI is changing that, and we’re proud to be driving this shift.”

Cellbyte was founded in 2024 by Daniel Moreira, Felix Steinbrenner and Samuel Moreira. The team’s combined expertise across the pharmaceutical industry, AI/machine learning and company building makes Cellbyte uniquely equipped to reshape drug launches for the AI era. Daniel brings direct experience from working in pharmaceutical consulting and dealing with legacy data storage practices that make it difficult to answer the critical questions that inform drug launches. Samuel brings technical expertise in building AI and machine learning applications. Felix brings operator acumen as a second-time and Y-Combinator alumnus founder.   

The company has been experiencing rapid growth, reaching six figures in ARR just weeks after launching and expanding coverage into key global markets. It has secured contracts with global pharmaceutical brands such as Bayer and is consistently onboarding more.

With the new funds, Cellbyte plans to triple its headcount and expand its engineering capabilities to meet this growing customer demand. The investment will maintain Cellbyte’s trajectory of impressive ARR growth as it aims to become the go-to operating system for commercial pharmaceutical teams worldwide.

William McQuillan, Partner at Frontline Ventures said: “Cellbyte is tackling one of pharma’s biggest bottlenecks with an AI-driven strategy. Felix, Samuel and Daniel have set their sights globally from day one, and we're proud to support them as they expand into the US, accelerating patient access to new treatments.”

For more startup news, check out the other articles on the website, and subscribe to the magazine for free. Listen to The Cereal Entrepreneur podcast for more interviews with entrepreneurs and big-hitters in the startup ecosystem.